Liver cancer is a type cancer in which malignant cells gets formed in the liver tissues. There are two types of liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma (also known as bile duct cancer). Hepatocellular is a type of adenocarcinoma and the most common type of liver cancer. Liver cirrhosis or hepatitis is observed as the major risk factor for liver cancer. Liver cancer is characterized by hard lump formation (at the right side of rib cage), abdominal discomfort, pain around shoulder, easy bleeding, loss of appetite, weight loss, fever, pale bowel movements or dark urine, and weakness. Liver cancer can be diagnosed by biopsy, ultrasound test, magnetic resonance imaging, serum tumour marker test, liver function test, and computed tomography. Jiangsu HengRui Medicine Co., Ltd. is in the process of developing SHR-1210 as a PDCD 1 protein inhibitor for the treatment of liver cancer. H. Lee Moffitt Cancer Center and Research Institute is in the process of developing trametinib as a MAP kinase inhibitor for the treatment of liver cancer. Some of the companies having the pipeline liver cancer include Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb Company and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.